Background, methods: We analyzed pooled data from 2477 patients with T2DM (mean [SD] age 55.6 [10.2] years, HbA1c 7.99 [0.85]%, BMI 28.7 [5.5] kg/m2) from four randomized, placebo-controlled Phase III trials that investigated empagliflozin (EMPA) 10 mg or 25 mg given for 24 weeks as monotherapy, add-on to metformin (MET), add-on to MET + SU, or add-on to pioglitazone ± MET.
No takes yet. Share an insight, caveat, or question.
Hach et al. (2014) studied this question.